Volanakis JE, Frank MM. The human complement system in health and disease. New York: Marcel Dekker, Inc., 1998.10.1201/b14212Search in Google Scholar
Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004;5:981-6.10.1038/ni1113Search in Google Scholar
O’Shea JJ, Brown EJ, Gaither TA, Takahashi T, Frank MM. Tumor-promoting phorbol esters induce rapid internalization of the C3b receptor via a cytoskeleton-dependent mechanism. J Immunol 1985;135:1325-30.Search in Google Scholar
Hugli TE, Muller-Eberhard HJ. Anaphylatoxins: C3a and C5a. Adv Immunol 1978;26:1-53.10.1016/S0065-2776(08)60228-XSearch in Google Scholar
Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 1996;61:201-83.10.1016/S0065-2776(08)60868-8Search in Google Scholar
Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Livingstone, 2004.10.1016/B978-0-443-08559-8.50012-1Search in Google Scholar
Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990;30: 583-90.10.1046/j.1537-2995.1990.30790385515.xSearch in Google Scholar
Sazama K. Transfusion errors: scope of the problem, consequences, and solutions. Curr Hematol Rep 2003;2:518-21.Search in Google Scholar
Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest 1972; 51:583-9.10.1172/JCI106847Search in Google Scholar
Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford, England: Blackwell Science, 1997.Search in Google Scholar
Fischer JT, Petz LD, Garratty G, Cooper NR. Correlations between quantitative assay of red cell-bound C3, serologic reactions, and hemolytic anemia. Blood 1974;44:359-73.10.1182/blood.V44.3.359.359Search in Google Scholar
Hourcade D, Liszewski MK, Krych-Goldberg M, Atkinson JP. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology 2000;49:103-16.10.1016/S0162-3109(00)80296-9Search in Google Scholar
Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981;153:1138-50.10.1084/jem.153.5.113821861516910481Search in Google Scholar
Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 1979;76:5867-71.10.1073/pnas.76.11.5867Search in Google Scholar
Ross GD. Complement receptor type 1. Curr Top Microbiol Immunol 1992;178:31-44.10.1007/978-3-642-77014-2_3Search in Google Scholar
Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 1997;7:345-55.10.1016/S1074-7613(00)80356-8Search in Google Scholar
Ghiran I, Barbashov SF, Klickstein LB, et al. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med 2000;192:1797-1808.10.1084/jem.192.12.1797Search in Google Scholar
Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989;46:183-219.10.1016/S0065-2776(08)60654-9Search in Google Scholar
Nelson RA. The immune adherence phenomenon: an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 1953;118:733-7.10.1126/science.118.3077.733Search in Google Scholar
Cooper NR. Immune adherence by the fourth component of complement. Science 1969;165: 396-8.10.1126/science.165.3891.396Search in Google Scholar
Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 1980;152:20-30.10.1084/jem.152.1.20Search in Google Scholar
Paccaud JP, Carpentier JL, Schifferli JA. Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J Immunol 1988;141:3889-94.Search in Google Scholar
Cornacoff JB, Hebert LA, Smead WL, et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 1983;71:236-47.10.1172/JCI110764Search in Google Scholar
Gigli I, Nelson RA, Jr. Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3. Exp Cell Res 1968;51:45-67.10.1016/0014-4827(68)90158-4Search in Google Scholar
Brown EJ. Complement receptors and phagocytosis. Curr Opin Immunol 1991;3:76-82.10.1016/0952-7915(91)90081-BSearch in Google Scholar
Molina H, Holers VM, Li B, et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA 1996;93:3357-61.10.1073/pnas.93.8.3357Search in Google Scholar
Kozono Y, Abe R, Kozono H, et al. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol 1998;160:1565-72.Search in Google Scholar
Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Ann Rev Immunol 2000;18:393-422.10.1146/annurev.immunol.18.1.393Search in Google Scholar
Gray D, Kumararatne DS, Lortan J, Khan M, MacLennan IC. Relation of intra-splenic migration of marginal zone B cells to antigen localization on follicular dendritic cells. Immunology 1984;52: 659-69.Search in Google Scholar
Enriquez-Rincon F, Andrew E, Parkhouse RM, Klaus GG. Suppression of follicular trapping of antigen-antibody complexes in mice treated with anti-IgM or anti-IgD antibodies from birth. Immunology 1984;53:713-9.Search in Google Scholar
Pozdnyakova O, Guttormsen HK, Lalani FN, Carroll MC, Kasper DL. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J Immunol 2003;170:84-90.10.4049/jimmunol.170.1.84Search in Google Scholar
Brown JC, Harris G, Papamichail M, Sljivic VS, Holborow EJ. The localization of aggregated human-globulin in the spleens of normal mice. Immunology 1973;24:955-68.Search in Google Scholar
Kroese FG, Wubbena AS, Nieuwenhuis P. Germinal centre formation and follicular antigen trapping in the spleen of lethally X-irradiated and reconstituted rats. Immunology 1986;57:99-104.Search in Google Scholar
Van den Berg TK, Yoshida K, Dijkstra CD. Mechanism of immune complex trapping by follicular dendritic cells. Curr Top Microbiol Immunol 1995;201:49-67.10.1007/978-3-642-79603-6_3Search in Google Scholar
Fischer MB, Ma M, Hsu NC, Carroll MC. Local synthesis of C3 within the splenic lymphoid compartment can reconstitute the impaired immune response in C3-deficient mice. J Immunol 1998;160:2619-25.Search in Google Scholar
Zandvoort A, Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002;130:4-11.10.1046/j.1365-2249.2002.01953.xSearch in Google Scholar
Wilson JG, Tedder TF, Fearon DT. Characterization of human T lymphocytes that express the C3b receptor. J Immunol 1983;131:684-9.Search in Google Scholar
Yaskanin DD, Thompson LF, Waxman FJ. Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes. Cell Immunol 1992;142:159-176.10.1016/0008-8749(92)90277-VSearch in Google Scholar
Rodgaard A, Thomsen BS, Bendixen G, Bendtzen K. Increased expression of complement receptor type 1 (CR1, CD35) on human peripheral blood T lymphocytes after polyclonal activation in vitro. Immunol Res 1995;14:69-76.10.1007/BF029184987561342Search in Google Scholar
Mouhoub A, Delibrias CC, Fischer E, Boyer V, Kazatchkine MD. Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV-infected cells. Clin Exp Immunol 1996;106:297-303.10.1046/j.1365-2249.1996.d01-844.x22005958918576Search in Google Scholar
Kinoshita T, Takeda J, Hong K, et al. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J Immunol 1988;140:3066-72.Search in Google Scholar
Cockburn IA, Mackinnon MJ, O’Donnell A, et al. A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci USA 2004;101:272-7.10.1073/pnas.030530610131417514694201Search in Google Scholar
Cohen JH, Atkinson JP, Klickstein LB, et al. The C3b/C4b receptor (CR1, CD35) on erythrocytes: methods for study of the polymorphisms. Mol Immunol 1999;36:819-25.10.1016/S0161-5890(99)00102-9Search in Google Scholar
Klickstein LB, Wong WW, Smith JA, et al. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med 1987; 165:1095-1112.10.1084/jem.165.4.1095Search in Google Scholar
Klickstein LB, Bartow TJ, Miletic V, et al. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 1988;168: 1699-1717.10.1084/jem.168.5.1699Search in Google Scholar
Fingeroth JD, Benedict MA, Levy DN, Strominger JL. Identification of murine complement receptor type 2. Proc Natl Acad Sci USA 1989;86:242-6.10.1073/pnas.86.1.242Search in Google Scholar
Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol 1990;145:2974-83.Search in Google Scholar
Kurtz CB, O’Toole E, Christensen SM, Weis JH. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol 1990;144:3581-91.Search in Google Scholar
Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev 1998;50:59-87.Search in Google Scholar
Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-51.10.1126/science.2371562Search in Google Scholar
Perry GJ, Eisenberg PR, Zimmerman JI, Levin J. Phase I safety trial of soluble complement receptor 1 (TP10) in acute myocardial infarction. J Am Coll Cardiol 1998;31:411A.10.1016/S0735-1097(98)80133-2Search in Google Scholar
Zamora MR, Davis RD, Keshavjee SH, et al. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 1999;116:46S.10.1378/chest.116.suppl_1.46SSearch in Google Scholar
Zimmerman JL, Dellinger RP, Straube RC, Levin JL. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000;28:3149-54.10.1097/00003246-200009000-0000411008973Search in Google Scholar
Yazdanbakhsh K, Kang S, Tamasauskas D, Sung D, Scaradavou A. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 2003;101:5046-52.10.1182/blood-2002-10-306812576307Search in Google Scholar
Yazdanbakhsh K, Scaradavou A. CR1-based inhibitors for prevention of complement-mediated immune hemolysis. Drug Design and Perspectives 2004; 17(5): 314-20.10.1358/dnp.2004.17.5.82903515334181Search in Google Scholar
Krych M, Clemenza L, Howdeshell D, et al. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem 1994;269:13273-8.10.1016/S0021-9258(17)36829-1Search in Google Scholar
Krych M, Hauhart R, Atkinson JP. Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem 1998;273:8623-9.10.1074/jbc.273.15.8623Search in Google Scholar
Krych-Goldberg M, Hauhart RE, Subramanian VB, et al. Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases. J Biol Chem 1999;274:31160-8.10.1074/jbc.274.44.31160Search in Google Scholar
Mqadmi A, Abdullah Y, Yazdanbakhsh K. Characterization of complement receptor 1 domains for prevention of complement-mediated red cell destruction. Transfusion 2005;45(2):234-44.10.1111/j.1537-2995.2004.04163.xSearch in Google Scholar
Scesney SM, Makrides SC, Gosselin ML, et al. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. Eur J Immunol 1996;26:1729-35.10.1002/eji.1830260810Search in Google Scholar
Mulligan MS, Warner RL, Rittershaus CW, et al. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J Immunol 1999;162:4952-9.Search in Google Scholar
Makrides SC, Scesney SM, Ford PJ, et al. Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement. J Biol Chem 1992;267:24754-61.10.1016/S0021-9258(18)35828-9Search in Google Scholar
Krych M, Hourcade D, Atkinson JP. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci USA 1991;88:4353-7.10.1073/pnas.88.10.4353Search in Google Scholar
Reilly BD, Makrides SC, Ford PJ, Marsh HC, Jr., Mold C. Quantitative analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor (CR1). J Biol Chem 1994;269:7696-7701.10.1016/S0021-9258(17)37343-XSearch in Google Scholar
Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol Immunol 2003;40:159-70.10.1016/S0161-5890(03)00111-1Search in Google Scholar
Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227-324.10.1016/S0065-2776(01)76021-XSearch in Google Scholar
Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.Search in Google Scholar
Botto M, Dell’Agnola C, Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genet 1998;19:56-9.10.1038/ng0598-56Search in Google Scholar
Miyakawa Y, Yamada A, Kosaka K, et al. Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus. Lancet 1981;2:493-7.10.1016/S0140-6736(81)90882-5Search in Google Scholar
Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum 1986;29:739-47.10.1002/art.1780290606Search in Google Scholar
Levy E, Ambrus J, Kahl L, et al. T lymphocyte expression of complement receptor 2 (CR2/ CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol 1992;90: 235-44.10.1111/j.1365-2249.1992.tb07935.xSearch in Google Scholar
Marquart HV, Svendsen A, Rasmussen JM, et al. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995;101:60-5.10.1111/j.1365-2249.1995.tb02277.xSearch in Google Scholar
Emancipator SN, Iida K, Nussenzweig V, Gallo GR. Monoclonal antibodies to human complement receptor (CR1) detect defects in glomerular diseases. Clin Immunol Immunopathol 1983;27: 170-5.10.1016/0090-1229(83)90067-3Search in Google Scholar
Kazatchkine MD, Fearon DT, Appay MD, Mandet C, Bariety J. Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus. J Clin Invest 1982;69:900-12.10.1172/JCI1105293701447042757Search in Google Scholar
Jones J, Laffafian I, Cooper AM, Williams BD, Morgan BP. Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br J Rheumatol 1994;33:707-12.10.1093/rheumatology/33.8.7078055195Search in Google Scholar
Thomsen BS, Oxholm P, Manthorpe R, Nielsen H. Complement C3b receptors on erythrocytes, circulating immune complexes, and complement C3 split products in patients with primary Sjogren’s syndrome. Arthritis Rheum 1986;29:857-62.10.1002/art.17802907072943291Search in Google Scholar
Ruuska PE, Ikaheimo I, Silvennoinen-Kassinen S, Kaar ML, Tiilikainen A. Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon? Clin Exp Immunol 1992;89:18-21.10.1111/j.1365-2249.1992.tb06870.x15544081352745Search in Google Scholar
Takahashi K, Kozono Y, Waldschmidt TJ, et al. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol 1997;159:1557-69.Search in Google Scholar
Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998;9:721-31.10.1016/S1074-7613(00)80669-XSearch in Google Scholar
Adams EM, Brown MC, Nunge M, Krych M, Atkinson JP. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol 1991;147:3005-11.Search in Google Scholar
Kemper C, Chan AC, Green JM, et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003;421: 388-92.10.1038/nature0131512540904Search in Google Scholar
Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.10.1146/annurev.immunol.21.120601.14112215032588Search in Google Scholar
Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004;4:408-14.10.1016/j.coph.2004.05.00115251137Search in Google Scholar
Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.Search in Google Scholar
Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000;18:423-49.10.1146/annurev.immunol.18.1.42310837065Search in Google Scholar
Kuniyasu Y, Takahashi T, Itoh M, et al. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 2000;12:1145-55.10.1093/intimm/12.8.114510917889Search in Google Scholar
Lehmann J, Huehn J, de la RM, et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25-regulatory T cells. Proc Natl Acad Sci USA 2002;99:13031-6.10.1073/pnas.19216289913058112242333Search in Google Scholar
Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002;169:2461-5.10.4049/jimmunol.169.5.246112193715Search in Google Scholar
Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164: 183-90.10.4049/jimmunol.164.1.18310605010Search in Google Scholar
Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10: 1969-80.10.1093/intimm/10.12.19699885918Search in Google Scholar
Jonuleit H, Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-94.10.1084/jem.193.11.1285219338011390435Search in Google Scholar
Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-10.10.1084/jem.193.11.1303219338411390437Search in Google Scholar
Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-1302.10.1084/jem.193.11.1295219337611390436Search in Google Scholar
Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.10.4049/jimmunol.167.3.124511466340Search in Google Scholar
Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001;182:58-67.10.1034/j.1600-065X.2001.1820104.x11722623Search in Google Scholar
Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96.10.1084/jem.188.2.28722124619670041Search in Google Scholar
Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167: 1137-40.10.4049/jimmunol.167.3.113711466326Search in Google Scholar
Caramalho I, Lopes-Carvalho T, Ostler D, et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003;197:403-11.10.1084/jem.20021633219385812591899Search in Google Scholar
Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841-55.10.1038/nri148515516964Search in Google Scholar
Araujo MI, Hoppe BS, Medeiros M, Jr., Carvalho EM. Schistosoma mansoni infection modulates the immune response against allergic and autoimmune diseases. Mem Inst Oswaldo Cruz 2004; 99:27-32.10.1590/S0074-02762004000900005Search in Google Scholar
Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-44.Search in Google Scholar
Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002;69:258-71.10.1002/ajh.1006211921020Search in Google Scholar
Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001;2:797-801.10.1038/ni0901-79711526389Search in Google Scholar
Kalli KR, Hsu PH, Bartow TJ, et al. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2- F(ab')2 chimeric complement inhibitor. J Exp Med 1991;174:1451-60.10.1084/jem.174.6.145121190551836011Search in Google Scholar
